Prolonged adjuvant anastrozole confers no DFS benefit in postmenopausal breast cancer
1 month ago - By Healio
A longer duration of extended hormone therapy provided no benefit for postmenopausal women with hormone receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy, according to randomized phase 3 study results.
The findings - published in The New England Journal of Medicine - showed no statistically significant difference in DFS between women who received 5 years vs. 2 years of extended hormone therapy.
In addition, women who received extended therapy demonstrated a higher risk for adverse effects and bone fracture.
“In this trial, we did not
Read more ...